Have a feature idea you'd love to see implemented?
Let us know!
FDMT 4D Molecular Therapeutics Inc
Price (delayed)
$7.99
Market cap
$369.36M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.85
Enterprise value
$206.65M
4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector
Highlights
The company's equity has surged by 68% YoY but it fell by 6% QoQ
FDMT's revenue has dropped by 100% year-on-year and by 100% since the previous quarter
The gross profit has dropped by 100% year-on-year and by 100% since the previous quarter
Key stats
What are the main financial stats of FDMT
Market
Valuations
Earnings
Shares outstanding
46.23M
Market cap
$369.36M
Enterprise value
$206.65M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.75
Price to sales (P/S)
26,110.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12,156.14
Revenue
$17,000
EBIT
-$143.48M
EBITDA
-$137.05M
Free cash flow
-$116.76M
Per share
Balance sheet
Liquidity
EPS
-$2.85
Free cash flow per share
-$2.1
Book value per share
$10.64
Revenue per share
$0
TBVPS
$10.87
Total assets
$604.03M
Total liabilities
$51.08M
Debt
$24.83M
Equity
$552.95M
Working capital
$481.29M
Debt to equity
0.04
Current ratio
17.33
Quick ratio
17.03
Net debt/EBITDA
1.19
Margins
Efficiency
Dividend
EBITDA margin
-806,152.9%
Gross margin
100%
Net margin
-844,000%
Operating margin
-990,447.1%
Return on assets
-26.2%
Return on equity
-28%
Return on invested capital
-45%
Return on capital employed
-25%
Return on sales
-844,000%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FDMT stock price
How has the 4D Molecular Therapeutics stock price performed over time
Intraday
-4.99%
1 week
-0.37%
1 month
-6.88%
1 year
-33.14%
YTD
-60.56%
QTD
-26.09%
Financial performance
How have 4D Molecular Therapeutics's revenue and profit performed over time
Revenue
$17,000
Gross profit
$17,000
Operating income
-$168.38M
Net income
-$143.48M
Gross margin
100%
Net margin
-844,000%
FDMT's revenue has dropped by 100% year-on-year and by 100% since the previous quarter
The gross profit has dropped by 100% year-on-year and by 100% since the previous quarter
The operating income has shrunk by 60% YoY and by 28% QoQ
The company's net income fell by 50% YoY and by 31% QoQ
Growth
What is 4D Molecular Therapeutics's growth rate over time
Valuation
What is 4D Molecular Therapeutics stock price valuation
P/E
N/A
P/B
0.75
P/S
26,110.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12,156.14
4D Molecular Therapeutics's EPS has decreased by 24% from the previous quarter and by 4.4% YoY
The stock's P/B is 69% below its 5-year quarterly average of 2.4 and 64% below its last 4 quarters average of 2.1
The company's equity has surged by 68% YoY but it fell by 6% QoQ
The P/S is 194% higher than the last 4 quarters average of 8874.6
FDMT's revenue has dropped by 100% year-on-year and by 100% since the previous quarter
Efficiency
How efficient is 4D Molecular Therapeutics business performance
The return on invested capital rose by 32% year-on-year and by 3% since the previous quarter
The return on equity is up by 19% year-on-year but it has declined by 16% since the previous quarter
The ROA has grown by 17% YoY but it has contracted by 16% from the previous quarter
Dividends
What is FDMT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FDMT.
Financial health
How did 4D Molecular Therapeutics financials performed over time
4D Molecular Therapeutics's total assets has soared by 67% YoY but it has decreased by 2.6% from the previous quarter
The total liabilities has soared by 61% YoY and by 61% from the previous quarter
The company's debt is 96% lower than its equity
FDMT's debt to equity has surged by 100% since the previous quarter but it is down by 20% year-on-year
The company's debt has surged by 82% QoQ and by 64% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.